Hospital surgical volume, utilization, costs and outcomes of retroperitoneal lymph node dissection for testis cancer
- PMID: 22550481
- PMCID: PMC3328891
- DOI: 10.1155/2012/189823
Hospital surgical volume, utilization, costs and outcomes of retroperitoneal lymph node dissection for testis cancer
Abstract
Objectives. Retroperitoneal lymph node dissection (RPLND) outcomes for testis cancer originate mostly from single-center series. We characterized population-based utilization, costs, and outcomes and assessed whether higher volume affects outcomes. Methods and Materials. Using the US Nationwide Inpatient Sample from 2001-2008, we identified 993 RPLND and used propensity score methods to assess utilization, costs, and inpatient outcomes based on hospital surgical volume. Results. 51.6% of RPLND were performed at hospitals where there were two or fewer cases per year. RPLND was more commonly performed at large urban teaching hospitals, where men were younger, more likely to be white and earning incomes exceeding the 50th percentile (all P ≤ .05). Higher hospital volumes were associated with fewer complications and more routine home discharges (all P ≤ .047). However, higher volume hospitals had more transfusions (P = .004) and incurred $1,435 more in median costs (P < .001). Limitations include inability to adjust for tumor characteristics and absence of outpatient outcomes. Conclusions. Sociodemographic differences exist between high versus low volume RPLND hospitals. Although higher volume hospitals had more transfusions and higher costs, perhaps due to more complex cases, they experienced fewer complications. However, most RPLND are performed at hospitals where there were two or fewer cases per year.
Similar articles
-
Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors.World J Urol. 2021 Jun;39(6):1977-1984. doi: 10.1007/s00345-020-03403-9. Epub 2020 Aug 14. World J Urol. 2021. PMID: 32797261
-
Contemporary retroperitoneal lymph node dissection (RPLND) for testis cancer in the UK - a national study.BJU Int. 2017 Jan;119(1):91-99. doi: 10.1111/bju.13569. Epub 2016 Jul 30. BJU Int. 2017. PMID: 27353395
-
[Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].Zhonghua Wai Ke Za Zhi. 2017 Aug 1;55(8):603-607. doi: 10.3760/cma.j.issn.0529-5815.2017.08.010. Zhonghua Wai Ke Za Zhi. 2017. PMID: 28789511 Chinese.
-
Laparoscopic retroperitoneal lymph node dissection: does it still have a role in the management of clinical stage I nonseminomatous testis cancer? A European perspective.Eur Urol. 2008 Nov;54(5):1004-15. doi: 10.1016/j.eururo.2008.08.022. Epub 2008 Aug 13. Eur Urol. 2008. PMID: 18722704 Review.
-
Laparoscopic retroperitoneal lymph node dissection for testicular cancer.Arab J Urol. 2012 Mar;10(1):66-73. doi: 10.1016/j.aju.2012.01.001. Epub 2012 Feb 14. Arab J Urol. 2012. PMID: 26558006 Free PMC article. Review.
Cited by
-
Retroperitoneal lymph node dissection for testicular cancer is a demanding procedure: detailed real-life data of complications and additional surgical procedures in 295 cases.World J Urol. 2023 Sep;41(9):2397-2404. doi: 10.1007/s00345-023-04516-7. Epub 2023 Jul 25. World J Urol. 2023. PMID: 37490059 Free PMC article.
-
Outcomes of Postchemotherapy Retroperitoneal Lymph Node Dissection from a High-volume UK Centre Compared with a National Data Set.Eur Urol Open Sci. 2021 Sep 30;33:83-88. doi: 10.1016/j.euros.2021.09.005. eCollection 2021 Nov. Eur Urol Open Sci. 2021. PMID: 34723218 Free PMC article.
-
Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors.World J Urol. 2021 Jun;39(6):1977-1984. doi: 10.1007/s00345-020-03403-9. Epub 2020 Aug 14. World J Urol. 2021. PMID: 32797261
-
Complex surgery and perioperative systemic therapy for genitourinary cancer of the retroperitoneum.Curr Oncol. 2020 Feb;27(1):e34-e42. doi: 10.3747/co.27.5713. Epub 2020 Feb 1. Curr Oncol. 2020. PMID: 32218666 Free PMC article.
-
A Review of Outcomes and Technique for the Robotic-Assisted Laparoscopic Retroperitoneal Lymph Node Dissection for Testicular Cancer.Adv Urol. 2018 May 3;2018:2146080. doi: 10.1155/2018/2146080. eCollection 2018. Adv Urol. 2018. PMID: 29853869 Free PMC article. Review.
References
-
- McKiernan JM, Goluboff ET, Liberson GL, Golden R, Fisch H. Rising risk of testicular cancer by birth cohort in the United States from 1973 to 1995. Journal of Urology. 1999;162(2):361–363. - PubMed
-
- Bray F, Richiardi L, Ekbom A, Pukkala E, Cuninkova M, Moller H. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. International Journal of Cancer. 2006;118(12):3099–3111. - PubMed
-
- Sun M, Abdollah F, Budaus L, et al. Trends of retroperitoneal lymphadenectomy use in patients with nonseminomatous germ cell tumor of the testis: a population-based study. Annals of Surgical Oncology. 2011;18(10):2997–3004. - PubMed
-
- Joudi FN, Konety BR. The impact of provider volume on outcomes from urological cancer therapy. Journal of Urology. 2005;174(2):432–438. - PubMed
-
- Healthcare cost and utilization project (HCUP) Overview of the nationwide inpatient sample. Rockville, MD, Agency for Healthcare Research and Quality, June 2010, http://www.hcup-us.ahrq.gov/nisoverview.jsp.
LinkOut - more resources
Full Text Sources
